Research & achievements研究・業績
Research paper研究論文-英文-
-
-
英文 原著他 (PubMed順）2022年度
Ischemic change in gastric mucosa due to gastric wall expansion with air supply: Real-time capture in upper gastrointestinal endoscopy Digestive Endoscopy / 2022
Matsuno K ,Sonoda T, Tanaka Y
-
-
-
英文 原著他 (PubMed順）2021年度
Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course Hepatol Res 51,P.239-244 / 2021
Tsuruya K, Anzai K, Shioyama S, Ito A, Arase Y, Hirose S , Tanaka Y, Suzuki H, Kagawa T.
Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization: a case report. Clin J Gastroenterol 14,P.251-257 / 2021
Yamamura K, Beppu T, Sato N, Oda E, Kinoshita K, Yuki H, Motohara T, Miyamoto H, Oda T, Akahoshi S
Hepatic Inflammatory Pseudotumor Mimicking Malignant Tumor With Rare Onset of Intra-abdominal Hemorrhage. Anticancer Res 41,P.2727-2732 / 2021
Yamamura K, Beppu T, Oda E, Sato N, Yuki H, Motohara T, Miyamoto H, Miyamura S, Onishi K, Komohara Y, Akahoshi S
Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor. Anticancer Res 41,P.5249-5254 / 2021
Oda E, Yamamura K, Hara Y, Matsumura K, Akahoshi S, Yuki H, Motohara T, Miyamoto H, Kinoshita K, Matsumura F, Ohnishi K, Komohara Y, Beppu T
Mac-2 binding protein and its glycan isomer: Where does it come from? Where is it going? Hepatol Res 51,P.1026-1028 / 2021
Nagaoka K ,Tanaka M, Tanaka Y.
Exosomal circCMTM3 promotes the pathogenesis of hepatocellular carcinoma via angiogenesis. Hepatol Res 51,P.1100-1101 / 2021
Watanabe T, Tanaka M.
Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy. Anticancer Res 41,P.5855-5861 / 2021
Adachi Y, Yamamura K, Yumoto S, Higashi T, Ishiodori H, Honda S, Hara Y, Matsumura K, Oda E, Akahoshi S, Yuki H, Miyamoto H, Doi K, Beppu T
A female patient with GSD IXc developing multiple and recurrent hepatocellular carcinoma: a case report and literature review. Hum Genome Var 8,P.45 / 2021
Kido J, Mitsubuchi H, Watanabe T, Sugawara K, Sasai H, Fukao T, Nakamura K.
"Improved visibility of early gastric cancer using a combination of chromoendoscopy and Texture and Color Enhancement Imaging" Gastrointest Endosc S0016-5107(21)01930-1. / 2021
Waki K, Kanesaka T, Michida T, Ishihara R, Tanaka Y.
-
-
-
英文 原著他 (PubMed順）2020年度
Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors. J Dermatol 47,P.e126-e147 / 2020
Mizukami Y, Kanemaru H, Nakamura K, Hashigo S, Kajihara I, Miyashita A, Aoi J, Fukushima S, Honda Y, Ihn H.
Successful treatment of adult-onset type II citrullinemia with a low-carbohydrate diet and L-arginine after DNA analysis produced a definitive diagnosis Clin J Gastroenterol 13,P.823-833 / 2020
Unita S, Hirashima N, Shimada M, Tsunekawa T, Tanaka D, Kondo T, Urata N, Kondo H, Saito M, Iwase H, Ito S, Togawa T, Saitoh S , Tanaka Y.
Cytomegalovirus enterocolitis in a patient with refractory immune-related colitis. Case Rep Gastroenterol 14,P.103-109 / 2020
Furuta Y, Miyamoto H, Naoe H, Shimoda M, Hinokuma Y, Miyamura T, Miyashita A, Fukushima S, Tanaka M, Sasaki Y
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy J Clin Exp Hematop 60,P.51-54 / 2020
Kikuchi T, Kusumoto S, Tanaka Y, Oshima Y, Fujinami H, Suzuki T, Totani H, Kinoshita S, Asao Y, Narita T, Ito A, Ri M, Komatsu H, Iida S.
Multiple Gastric Polyps Improved After Treatment for Ulcerative Colitis. Inflamm Bowel Dis 26,P.e144-e145 / 2020
Tsuruta Y, Furuta Y, Naoe H, Tanaka M
Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer Intern Med 59,P.2499-2504 / 2020
Higashi T, Miyamoto H, Yoshida R, Furuta Y, Nagaoka K, Naoe H, Naito H, Nakayama H, Tanaka M
Complete Removal of Adrenal Metastasis in Hepatocellular Carcinoma Using Indocyanine Green Fluorescent Imaging. Anticancer Res 40,P.5823-5828 / 2020
Yamamura K, Beppu T, Sato N, Kinoshita K, Oda E, Yuki H, Motohara T, Miyamoto H, Komohara Y, Akahoshi S
Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report. Anticancer Res 40,P.6465-6471 / 2020
Yamamura K, Beppu T, Kinoshita K, Oda E, Sato N, Yuki H, Motohara T, Miyamoto H, Kawaguchi H, Komohara Y, Akahoshi S
Cholangiolocarcinoma With Multiple Recurrences Successfully Treated With Repeated Liver Resection and Radiofrequency Ablation. Anticancer Res 40,P.7147-7153 / 2020
Sato N, Yamamura K, Oda E, Akahoshi S, Yuki H, Motohara T, Miyamoto H, Yoshii D, Komohara Y, Beppu T
-
-
-
英文 原著他 (PubMed順）2019年度
Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis. J Dermatol 46,P.e339-e341 / 2019
Miyashita A, Fukushima S, Tsukamoto H, Itai H, Miyamoto H, Nakahara S, Kubo Y, Kimura T, Kuriyama H, Ihn H
Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse? Clin J Gastroenterol 12,P.598-302 / 2019
Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N.
-
-
-
英文 原著他 (PubMed順）2018年度
Advanced parametric imaging for evaluation of Crohn’s disease using dual-energy computed tomography enterography. Radiol Case Rep 13,P.709-712 / 2022
Taguchi N, Oda S, Kobayashi T, Naoe H, Sasaki Y, Imuta M, Nakaura T, Yamashita Y
-
-
-
英文(PubMed順） 2022年度
Characterization of innate immune response to hepatitis B virus genotype F acute infection in tree shrew (Tupaia belangeri) model Front. Virol / 2022
Kayesh M-E-H, Hashem M-A, Sanada T, Kitab B, Rashid M-H-O, Akter L, Ezzikouri S, Murakami S, Ogawa S, Tanaka Y, Kohara M and Tsukiyama-Kohara K
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa J Glob Health / 2022
Vincent JP, Ndow G, Ogawa S, Ceesay A, Njie R, Sanneh B, Baldeh I, D’Alessandro U, Mendy M, Thursz M, Chemin I, Tanaka Y, Lemoine M, Shimakawa Y
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy J Hepatol 77,P.967-977 / 2022
Yuen M-F, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan J-Y, Lim S-G, Tanaka Y, Xie W, Yoon J-H, Duan Z, Kurosaki M, Sung-Park J, Labio M-E, Kumar R, Kweon Y-O, Yim H-J, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell F-M, Paff M, Theodore D.
Ischemic change in gastric mucosa due to gastric wall expansion with air supply: Real-time capture in upper gastrointestinal endoscopy Digestive Endoscopy / 2022
Matsuno K ,Sonoda T, Tanaka Y
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy J Hepatol / 2022
Man Fung Yuen1, Jeong Heo2, Hiromitsu Kumada3, Fumitaka Suzuki3, Yoshiyuki Suzuki4, Qing Xie5, Jidong Jia6, Yoshiyasu Karino7, Jinlin Hou8, Kazuaki Chayama9, Michio Imamura10, Judy Y. Lao-Tan11, SengGee Lim12, Tanaka Y, Wen Xie14, Jung-Hwan Yoon15, Zhongping Duan16, Masayuki Kurosaki17, Sung-Jae Park18, Madalinee Eternity Labio19, Rajneesh Kumar20, Young-Oh Kweon21, Hyung Joon Yim22, Yu Tao23, Jennifer Cremer24, Robert Elston25, Matt Davies26, Sharon Baptiste-Brown27, Kelong Han27, Fiona M. Campbell25, Melanie Paff27, Dickens Theodore24
Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings Clin Gastroenterol Hepatol / 2022
Shimakawa Y, Gibril Ndow,3,4 Théo Cerceau,1 Amie Ceesay,3 Atsushi Kaneko,5 Akira Hasegawa,5 Naoki Yamamoto,5 Katsumi Aoyagi,5 Jeanne Perpétue Vincent,1 Takehisa Watanabe,6 Masaya Baba,2 Bakary Sanneh,7 Ignatius Baldeh,7 Ramou Njie,8,9 Umberto D’Alessandro,3 Maimuna Mendy,10 Isabelle Chemin,11 Mark R. Thursz,4 Maud Lemoine,4 and Tanaka Y
Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation J Gastroenterol / 2022
Suzuki T,Inoue T,Matsuura K,Kusumoto S,Hagiwara S,Ogawa S,Yagi S,Kaneko A,Fujiwara K,Watanabe T,Aoyagi K,Urata Y,Tamori A,Kataoka H,Tanaka Y
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol. S0168-8278(22)00020-4. / 2022
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group.
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay. Hepatol Res / 2022
Hagiwara S, Kusumoto S, Inoue T, Ogawa S, Narita T, Ito A, Ri M, Komatsu H, Suzuki T, Matsuura K, Yagi S, Kaneko A, Aoyagi K, Iida S, Tanaka Y.
Blocking neddylation elicits antiviral effect against hepatitis B virus replication. Mol Biol Rep 49,P.403-412 / 2022
Abounouh K, Kayesh MEH, Altawalah H, Kitab B, Murakami S, Ogawa S, Tanaka Y, Dehbi H, Pineau P, Kohara M, Benjelloun S, Tsukiyama-Kohara K, Ezzikouri S.
Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. Liver Int. 42,P.124-134 / 2022
Inoue T, Funatsu Y, Ohnishi M, Isogawa M, Kawashima K, Tanaka M, Moriya K, Kawaratani H, Momoda R, Iio E, Nakagawa H, Suzuki Y, Matsuura K, Fujiwara K, Nakajima A, Yoshiji H, Nakayama J, Tanaka Y.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res 52,P.235-246 / 2022
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group.
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep. 12,P.1517 / 2022
Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T.
Mac-2-Binding Protein Glycan Isomer Predicts All Malignancies Post-sustained Virological Response in Chronic Hepatitis C Hepatol Commun / 2022
Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y, Tsubota A
Endoscopic direct clipping versus indirect clipping for colonic diverticular bleeding: A large multicenter cohort study United European Gastroenterol J 10,P.93-103 / 2022
Kishino T, Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Ishii N, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Kaise M.
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity Hepatol Res 52,P.105-119 / 2022
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K , Watanabe T,Setoyama H, Tanaka M, Tanaka Y.
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clin Gastroenterol Hepatol 20,P.874-885.e4 / 2022
Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong G LH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH．
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma. Hepatol Res 52,P.93-104 / 2022
Matsui T, Hamada-Tsutsumi S, Naito Y, Nojima M, Iio E, Tamori A, Kubo S, Ide T, Kondo Y, Eguchi Y, Komori A, Morine Y, Shimada M, Utsunomiya T, Shirabe K, Kimura K, Hiasa Y, Chuaypen N, Tangkijvanich P, Ito-Naiki A, Takahashi S, Ochiya T, Tanaka Y.
-
-
-
英文(PubMed順） 2021年度
Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 16,P.e0261878 / 2021
Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y.
Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers (Basel). 13,P.3455 / 2021
Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML.
The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency. Dig Dis / 2021
Shao X, Uojima H, Arai T, Ogawa Y, Setsu T, Atsukawa M, Furuichi Y, Arase Y, Horio K, Hidaka H, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Nakajima A, Terai S, Tanaka Y, Koizumi W.
A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One. 16,P.e0257166 / 2021
Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K.
Long-term outcomes after endoscopic resection for late elderly patients with early gastric cancer Gastrointest Endosc S0016-5107(21)01942-8. / 2021
Waki K, Shichijo S, Uedo N, Takeuchi Y, Maekawa A, Kanesaka T, Takeuchi Y, Higashino K, Ishihara R, Tanaka Y, Michida T.
Treatment strategies for reducing early and late recurrence of colonic diverticular bleeding based on stigmata of recent hemorrhage: a large multicenter study Gastrointest Endosc S0016-5107(21)01937-4 / 2021
Gobinet MS, Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Kishino T, Ishii N, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Uemura N, Itawa E, Sugimoto M, Fukuzawa M, Kawai T, Kaise M, Itoi T.
Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study BMC Gastroenterol 21,P.489 / 2021
Suzuki F, Suzuki Y, Karino Y, Tanaka Y, Kurosaki M, Yatsuhashi H, Atarashi T, Atsukawa M, Watanabe T, Enomoto M, Kudo M, Maeda N, Kohno H, Joko K, Michitaka K, Miki K, Takahashi K, Ide T, Fujiyama S,Kohno T, Itoh H, Tsukamoto S, Suzuki Y, Kawano Y,Sugiura W and Kumada H
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma Hepatol Commun 2021 Nov 27. doi: 10.1002/hep4.1872. / 2021
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y
Clinical impact of gastrointestinal endoscopy on the early detection of pharyngeal squamous cell carcinoma: A retrospective cohort study World J Gastrointest Endosc 13,P.491-501 / 2021
Miyamoto H, Naoe H, Morinaga J, Sakisaka K, Tayama S, Matsuno K, Gushima R, Tateyama M, Shono T, Imuta M, Miyamaru S, Murakami D, Orita Y and Tanaka Y.
Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B microorganisms 9,P.2083 / 2021
Watanabe T, Inoue T, Tanaka Y.
Blood‐Based Biomarkers in Hepatitis B Virus‐Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins Int. J. Mol. Sci 22,P.11051 / 2021
Hayashi S, Nagaoka K (equal 1st), Tanaka Y.
All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution J Chem Phys 155,P.145101 / 2021
Fujimoto K, Yamaguchi Y, Urano R, Shinoda W, Ishikawa T, Omagari K, Tanaka Y, Nakagawa A and Okazaki S
Outcomes in high and low volume hospitals in patients with acute hematochezia in a cohort study Sci Rep 11,P.20373 / 2021
Ishii N, Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Kishino T, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Omata F, Shiratori Y, Imamura N, Yano T, Kaise M.
Risk of pancreatitis following biliary stenting with/without endoscopic sphincterotomy: A randomized controlled trial. Clin Gastroenterol Hepatol S1542-3565(21)00872-7. / 2021
Kato S, Kuwatani M, Onodera M, Kudo T, Sano I, Katanuma A, Uebayashi M, Eto K, Fukasawa M, Hashigo S, Iwashita T, Yoshida M, Taya Y, Kawakami H, Kato H, Nakai Y, Kobashigawa K, Kawahata S, Shinoura S, Ito K, Kubo K, Yamato H, Hara K, Maetani I, Mukai T, Shibukawa G, Itoi T.
Identifying Bleeding Etiologies by Endoscopy Affected Outcomes in 10,342 Cases With Hematochezia: CODE BLUE-J Study Am J Gastroenterol 116,P.2222-2234 / 2021
Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Kishino T, Ishii N, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Fukuzawa M, Itoi T, Uemura N, Kawai T, Kaise M.
A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic Ascites. Liver Int 41,P.2944-2953 / 2021
Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y.
N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis. Glycobiology 31,P.1268-1278 / 2021
Noro E, Matsuda A, Kyoutou T, Sato T, Tomioka A, Nagai M, Sogabe M, Tsuruno C, Takahama Y, Kuno A, Tanaka Y, Kaji H, Narimatsu H.
Application of Fluorescent-Based Technology Detecting Protein-Protein Interactions to Monitor the Binding of Hepatitis B Virus X protein to DNA-damage-binding protein 1. BPPB 18,P.67-77 / 2021
Omagari K, Asamitsu K and Tanaka Y.
Co-continuous structural effect of size-controlled macro-porous glass membrane on extracellular vesicle collection for the analysis of miRNA. Sci Rep 11,P.8672 / 2021
Yukawa H, Yamazaki S, Aoki K, Muto K, Kihara N, Sato K, Onoshima D, Ochiya T, Tanaka Y, Baba Y.
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 75,P.302-310 / 2021
Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, Kaneko A, Matsuura K, Aoyagi K, Tanaka Y.
Modifed albumin–bilirubin grade to predict eligibility for second line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients Int J Clin Oncol 26,P.922-932 / 2021
Tokunaga T, Tanaka M, Tanaka K, Narahara S, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Tateyama M, Naoe H, Sasaki Y, Tanaka Y
Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation. Nat Metab 3,P.196-210 / 2021
Arima Y, Nakagawa Y, Takeo T, Ishida T, Yamada T,Hino S, Nakao M, Hanada S, Umemoto T, Suda T, Sakuma T, Yamamoto T, Watanabe T, Nagaoka K, Tanaka Y, Kawamura. K Y, Tonami K, Kurihara H, Sato Y, Yamagata K, Nakamura T, Araki S, Yamamoto E, Izumiya Y, Sakamoto K, Kaikita K, Matsushita K, Nishiyama K, Nakagata N and Tsujita K.
Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. Hepatol Res 51,P.528-537 / 2021
Chuaypen N, Chittmittrapap S, Avihingsanon A, Siripongsakun S, Wongpiyabovorn J, Tanpowpong N, Tanaka Y, Tangkijvanich P.
Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. Infect Dis. 24,P.1410-1421 / 2021
Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P.J
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy Cancer Sci 112,P.1943-1954 / 2021
Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Yasuhito Tanaka Y, Ueda R, Mizokami M, Kusumoto S.
Analysis of Hepatitis B virus genotype D in Greenland suggests presence of novel subgenotype . Front Microbiol 11,P.602296 / 2021
Bernardi Schneider A-de, Hostager R, Krarup H, Børresen M, Tanaka Y, Morriseau T, Osiowy C and Wertheim J-O.
Usefulness of an artificial intelligence system for the detection of esophageal squamous cell carcinoma evaluated with videos simulating overlooking situation Dig Endosc 33,P.1101-1109 / 2021
Waki K, Ishihara R, Kato Y, Shoji A, Inoue T, Matsueda K, Miyake M, Shimamoto Y, Fukuda H, Matsuura N, Ono Y, Yao K, Hashimoto S, Terai S, Ohmori M, Tanaka K, Kato M, Shono T, Miyamoto H, Tanaka Y, Tada T
Risk stratification for advanced colorectal neoplasia based on the findings of the index and first surveillance colonoscopies. PLoS One 16,P.e0245211 / 2021
Honda M, Naoe H, Honda M, Naoe H, Gushima R, Miyamoto H, Tateyama M, Oda Y, Murakami Y, Tanaka Y.
Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients infected patients. Sci Rep 11,P.960 / 2021
Imahashi M, Ode H, Kobayashi A, Nemoto M, Matsuda M, Hashiba C, Hamano A, Nakata Y, Mori M, Seko K，Nakahata M, Kogure A, Tanaka Y, Sugiura W, Yokomaku Y,Iwatani Y.
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol Int 15,P.71-81 / 2021
Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV J Hepatol 74,P.1075-1086 / 2021
Higashi-Kuwata N, Hayashi S, Kumamoto H, Ogata-Aoki H, Das D , Venzon D, Hattori S, Bulut H, Hashimoto M, Otagiri M, Takamune N, Kishimoto N, Davis A-D, Misumi S, Kakuni, M Tanaka Y, Mitsuya H.
Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1 Hepatology 73,P.1747-1763 / 2021
Bai X, Zhang H, Zhou Y, Nagaoka K, Ji C, Cao K, Mulla J, Cheng Z, Mueller W, Bay A, Hildebrand G, Lu S, Wallace J, Wands JR, Sun B*, Huang CK*.
Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin Gastroenterol Hepatol 19,P.46-60.e8 / 2021
Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey , Caviglia GP, Chen EQ, Cornberg M, Enomoto M, Honda M, Zu Siederdissen CH, Ishigami M, Janssen H, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJ, Wang B, Wei L, Yang HI, Yano Y, Yatsuhashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y.
-
-
-
英文(PubMed順） 2018年度
Impact of retroflexion in the right colon after repeated forward-view examinations. JGH open 2,P.282-287 / 2018
Miyamoto H, Naoe H, Oda Y, Shono T, Narita R, Oyama S, Hashigo S, Okuda A, Hasuda K, Tanaka M, Sakurai K, Murakami Y, Sasaki Y
Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver Transplant Proc 50,P.3858-3862 / 2018
Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y
Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. Open Forum Infect Dis 5,P.ofy268 / 2018
Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.
Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B Aliment Pharmacol Ther 48,P.1128-1137 / 2018
Hsu Y-C, Jun T, Huang Y-T, Yeh M-L, Lee C-L, Ogawa S, Cho S-H, Lin J-T, Yu M-L, Nguyen MH, Tanaka Y
Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer. Oncol Lett 16,P.5275-5281 / 2018
Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H.
Type I interferon signaling prevents hepatitis B virus-specific T cell responses by reducing antigen expression J Virol 92,P.e01099 / 2018
Kawashima K, Isogawa M, Hamada-Tsutsumi S, Baudi I, Saito S, Nakajima A, Tanaka Y
Intrahepatic Cross-Presentation and Hepatocellular Antigen Presentation Play Distinct Roles in the Induction of Hepatitis B Virus-Specific CD8 + T Cell Responses J Virol 92,P.e01099 / 2018
Murata Y, Kawashima K, Sheikh K, Tanaka Y, Isogawa M
Screening of microRNAs for a repressor of hepatitis B virus replication Oncotarget 9,P.29857-29868 / 2018
Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T, Tanaka Y
Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals Hepatol Int 12,P.356-367 / 2018
Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M
Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett 434,P.91-100 / 2018
Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, Suzuki M, Okuse C, Iwabuchi S, Nakano M, Akutsu N, Kang J-H, Matsui T, Yamada N, Sasaki H, Yamamoto E, Kai M, Sasaki Y, Sasaki S, Tanaka Y, Yotsuyanagi H, Tsutsumi T, Yamamoto H, Tokino T, Nakase H, Suzuki H, Itoh F
Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer Hepatol Res 48,P.1081-1091 / 2018
Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y
Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection Hepatol Res 48,P.1172-1177 / 2018
Tajiri H, Takano T, Tanaka Y, Murakami J, Brooks S
De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry Cell Chem Biol 25,P.906-915. e7 / 2018
Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T
Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells Mol Ther 26,P.1840-1854 / 2018
Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan J Gastroenterol 53,P.1276-1284 / 2018
Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T
Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma Hepatol Res 48,P.872-881 / 2018
Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, Tangkijvanich P
Gut dysbiosis associated with hepatitis C virus infection Clin Infect Dis 67,P.869-877 / 2018
Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment Hepatol Int 12,P.133-142 / 2018
Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K
Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status. CPT Pharmacometrics Syst Pharmacol 7,P.384-393 / 2018
Oniki K, Watanabe T, Kudo M,Izuka T, Ono T, Matsuda K,Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y,Watanabe H, Maruyama T, Otake K,Ogata Y, Saruwatari J
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease Hepatol Res 48,P.549-555 / 2018
Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K
Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers Hepatol Res 97,P.170-176 / 2018
Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y, Fujisaki J
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues J Gastroenterol 53,P.883-889 / 2018
Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y
Antiviral therapy for hepatitis B virus during second pregnancies J Obstet Gynaecol Res 44,P.566-569 / 2018
Wakano Y, Sugiura T, Endo T, Ito K, Suzuki M, Tajiri H, Tanaka Y, Saitoh S
Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis c virus genotype 1b infection with liver cirrhosis Intern Med 57,P.951-956 / 2018
Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W
Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus Hepatol Res 48,P.E203-E212 / 2018
Inoue T, Goto T, Iio E, Matsunami K, Fujiwara K, Shinkai N, Matsuura K, Matsui T, Nojiri S, Tanaka Y
Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy Clin Microbiol Infect 24,P.306. e7-306. e13 / 2018
Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P
Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease J Gastroenterol 53,P.438-448 / 2018
Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol 53,P.247-257 / 2018
Matsumoto A, Nishiguchi S, Enomoto H, Kang J-H, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan J Gastroenterol 53,P.119-128 / 2018
Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N
Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients Hepatol Res 48,P.134-143 / 2018
Shen S, Liang X, Hamed K, Tanaka Y, Omagari K, Fan R, Xie Q, Tan D, Zhou B, Jia J-D, Hou J, Sun J
-
-
-
英文(PubMed順） 2020年度
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort Hepatol Int 14,P.1023-1033 / 2020
Tanaka Y, Ogawa E, Huang C-F, Toyoda H, Won Jun D, Tseng C-H, Hsu Y-C, Enomoto M, Takahashi H, Furusyo N, Yeh M-L, Iio E, Yasuda S, Pui-Mei Lam C, Hyun Lee D, Haga H, L Yoon E, Bong Ahn S, Wong G, Nakamuta M, Nomura H, Tsai P-C, Han Jung J, Seon Song D, Dang H, Maeda M, Henry L, Cheung R, Yuen M-F, Ueno Y, Eguchi Y, Tamori A, Yu M-L, Hayashi J, Nguyen M H, REAL-C Investigators
Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study. BMC Gastroenterol 20,P.371 / 2020
Tateyama M, Naoe H, Tanaka M, Tanaka K, Narahara S, Tokunaga T, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Sasaki Y, Tanaka Y.
Prostaglandin E2-EP4 Axis Promotes Lipolysis and Fibrosis in Adipose Tissue Leading to Ectopic Fat Deposition and Insulin Resistance. Cell Rep 33,P.108265 / 2020
Inazumi T, Yamada K, Shirata N, Sato H, Taketomi Y, Morita K, Hohjoh H, Tsuchiya S, Oniki K, Watanabe T, Sasaki Y, Oike Y, Ogata Y, Saruwatari J, Murakami M, Sugimoto Y
Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA Virus Res 290,P.198191 / 2020
HoqueKayesha M-E, Amakod Y, Hashema M A, Murakami S, Ogawa S, Yamamoto N, Hifumi T, Miyoshi N, Sugiyama M ,Tanaka Y, Mizokami M, Kohara M, Tsukiyama-Kohara K.
Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture Int. J. Mol. Sci 21,P.7251 / 2020
Hamada-Tsutsumi S, Onishi M, Matsuura K, Isogawa M, Kawashima K, Sato Y, Tanaka Y.
Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology 20,P.1421-1427 / 2020
Tanaka H, Hijioka S, Hosoda W, Ueno M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Komoto I, Tsuji A, Hashigo S, Kanno A, Miyabe K, Takagi T, Ishii H, Kojima Y, Yoshitomi H, Yanagimoto H, Furuse J, Mizuno N.
Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus Hepatol Res 50,P.1128-1140 / 2020
Ito K, Angata K, Kuno A, Okumura A, Sakamoto K, Inoue R, Morita N, Watashi K, Wakita T, Tanaka Y, Sugiyama M, Mizokami M, Yoneda M, Narimatsu H
Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 40,P.2961-2971 / 2020
Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T.
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis Dig Dis Sci. 66,P.1080-1089 / 2020
Nagaoka K (equal 1st), Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK*.
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy Liver Cancer 9,P.207-220 / 2020
Tseng T.-C, Peng C.-Y, Hsu Y.-C, Su T.-H, Wang C.-C, Liu C.-J, Yang H.-C., Yang W.-T, Lin C.-H, Yu M.-L, Lai H.-C , Tanaka Y, Nguyen M.H , Liu C.-H , Chen P.-J , Chen D.-S , Kao J.-H.
The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism Liver Research 9,P.94-100 / 2020
Nagaoka K , Mulla J, Cao K, Cheng Z, Liu D, William Muellera Bay, A, Hildebrand, G, Lu, S, Huang, CK*.
"Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma" J Hepatol 73,P.285-293 / 2020
Kusumoto S, Tanaka Y (equal 1st), Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi 0, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M.
Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity Anal Biochem 597,P.113642 / 2020
ToyodaT, Wang Y, Wen Y, Tanaka Y.
Melinjo seed extract increases adiponectin multimerization in physiological and pathological conditions. Sci Rep 10,P.4313 / 2020
Oniki K, Kawakami T, Nakashima A, Miyata K, Watanabe T, Fujikawa H, Nakashima R, Nasu A, Eto Y, Takahashi N, Nohara H, Ann Suico M, Kotani S, Obata Y, Sakamoto Y, Seguchi Y, Saruwatari J, Imafuku T, Watanabe H, Maruyama T, Kai H,Shuto T.
Prometastatic Secretome Trafficking via Exosomes Initiates Pancreatic Cancer Pulmonary Metastasis. Cancer Lett 481,P.63-75 / 2020
Ogawa K, Lin Q, Li L, Bai X, Chen X, Chen H, Kong R, Wang Y, Zhu H, He F, Xu Q, Liu L, Li M, Zhang S, Nagaoka K, Carlson R, Safran H, Charpentier K, Sun B*, Wands J*, Dong X*
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: Hepatol Int 14,P.225-238 / 2020
Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima 6, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group.
A Pilot Study Assessing the Possible Combined Effect of Physical Activity and PNPLA3 rs738409 Polymorphism on the Risk for Non-Alcoholic Fatty Liver Disease in the Japanese Elderly General Population. Diabetes Metab Syndr Obes 13,P.333-341 / 2020
Muto N, Oniki K, Kudo M, Obata Y, Sakamoto Y, Tokumaru N, Izuka T, Watanabe T, Otake K, Ogata Y, Saruwatari J
7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety Antiviral Res 176,P.104744 / 2020
Hayashi S, Higashi-Kuwata N, Das D, Tomaya K, Yamada K, Murakami S, Venzon DJ, Hattori SI, Isogawa M, Sarafianos SG, Mitsuya H, Tanaka Y
JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol 55,P.640-652 / 2020
Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L, Hayashi N.
Tolloid-Like 1 Negatively Regulates Hepatic Differentiation of Human Induced Pluripotent Stem Cells Through Transforming Growth Factor Beta Signaling. Hepatol Commun 4,P.255-267 / 2020
Kiso A, Toba Y, Tsutsumi S, Deguchi S, Igai K, Koshino S, Tanaka Y, Takayama K, Mizuguchi H.
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. J Gastroenterol Hepatol 35,P.1420-1425 / 2020
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T.
MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. Cancer Sci 111,P.869-880 / 2020
Yasukawa K, Liew LC, Hagiwara K, Hironaka-Mitsuhashi A, Qin XY, Furutani Y, Tanaka Y, Nakagama H, Kojima S, Kato T, Ochiya T, Gailhouste L.
Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. Carcinogenesis 41,P.1145-1157 / 2020
Naiki-Ito A, Naiki T, Kato H, Iida K, Etani T, Nagayasu Y, Suzuki S, Yamashita Y, Inaguma S, Onishi M, Tanaka Y, Yasui T, Takahashi S.
HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. Clin Infect Dis 71,P.2840-2848 / 2020
Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; REAL-C Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL. Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL.
Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc 91,P.373-381.e2. / 2020
Kurita A, Yasukawa S, Zen Y, Yoshimura K, Ogura T, Ozawa E, Okabe Y, Asada M, Nebiki H, Shigekawa M, Ikeura T, Eguchi T, Maruyama H, Ueki T, Itonaga M, Hashimoto S, Shiomi H, Minami R, Hoki N, Takenaka M, Itokawa Y, Uza N, Hashigo S, Yasuda H, Takada R, Kamada H, Kawamoto H, Kawakami H, Moriyama I, Fujita K, Matsumoto H, Hanada K, Takemura T, Yazumi S.
Tenofovir versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B Am J Gastroenterol 115,P.271-280 / 2020
Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.
Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. Hepatology 71,P.1910-1922 / 2020
Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML Toyoda H, Nguyen MH.
Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection. J Gastroenterol Hepatol 35,P.855-861 / 2020
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T
Risk stratification of advanced colorectal neoplasia after baseline colonoscopy: Cohort study of 17 Japanese community practices. Dig Endosc 32,P.106-113 / 2020
Shono T, Oyama S, Oda Y, Yokomine K, Murakami Y, Miyamoto H, Tanaka M, Naoe H, Sasaki Y ,Kumamoto Colon Cancer, Study Group
Endoscopic features of esophageal adenocarcinoma derived from short-segment versus long-segment Barrett’s esophagus J Gastroenterol Hepatol 35,P.211-217 / 2020
Yamasaki A, Shimizu T, Kawachi H, Yamamoto N, Yoshimizu S, Horiuchi Y, Ishiyama A, Yoshio T, Hirasawa T, Tsuchida T, Sasaki Y, Fujisaki J
-
-
-
英文(PubMed順） 2019年度
Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. PLoS One 14,P.e0224184 / 2019
Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K.
Hepatitis B virus-related hepatocellular carcinoma in young adults Efficacy of nationwide selective vaccination. Hepatol Res 50,P.182-189 / 2019
Yotsuyanagi H, Takano T, Tanaka M, Amano K, Imamura M, Ogawa K, Yasunaka T, Yasui Y, Hayashi K, Tanaka Y, Tajiri H; for Japanese adolescent HBV-HCC study group.
Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: a prospective 3-year observational study Nutr Metab Cardiovasc Dis 29,P.1337-1344 / 2019
Sugiura T, Dohi Y, Takase H, Yamashita S, Tsuzuki Y, Ogawa S, Tanaka Y, Ohte N.
Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway J Hematol Oncol. 12,P.144-144 / 2019
Ogawa K,Lin Q,LiLe,Bai X,Chen X,Chen H,Kong R,Wang Y,Zhu H,He F,Xu Q,Liu L,Li M,Zhang S, Nagaoka K,Carlson R,Safran H,Charpentier K,Sun B,Wands J,Dong
The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection. Sci Rep 9,P.13393 / 2019
Kondo Y, Kogure T, Ninomiya M, Fukuda R, Monma N, Ikeo K, Tanaka Y.
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium Hepatol Int 13,P.587-598 / 2019
Huang C-F, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu Y-C, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu C-H, Tada T, Chuang W-L, Cheung R, Hayashi J, Tseng C-H, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang J-F, Tai C-M, Lo G-H, Lee M-H, Yang H-I, Kao J-H, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu M-L, Nguyen MH, For the REAL-C Investigators
MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells Cell Death Dis 10,P.553 / 2019
Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Kato T, Nakagama H, Ochiya T
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat 26,P.1266-1275 / 2019
Ikeda H, Waanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.
Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia Exp. Ther. Med 18,P.596-604 / 2019
Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S,Kato M,Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H,Shibakoge M,Takaguchi K, Hattori T, Sata M, Koike K
Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems. Antiviral Res 169,P.104537 / 2019
Nio Y, Sasai M, Akahori Y, Okamura H, Hasegawa H, Oshima M, Watashi K, Wakita T, Ryo A, Tanaka Y, Hijikata M
Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan Open Forum Infect Dis 6,P.ofz185 / 2019
Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T
Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production J Virol 93,P.e00621 / 2019
Inoue J, Ninomiya M, Umetsu T, Nakamura T, Kogure T, Kakazu E, Iwata T, Takai S, Sano A, Fukuda M, Watashi K, Isogawa M, Tanaka Y, Shimosegawa T, McNiven MA, Masamune A
Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma Cancer Lett 449,P.87-98 / 2019
Nagaoka K, Bai X, Ogawa K, Dong X, Zhang S, Zhou Y, Carlson RI, Jiang ZG, Fuller S, Lebowitz MS, Ghanbari H, Wands JR
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis J Hepatol 71,P.473-485 / 2019
Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu P-S, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour J-F, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH
Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection Hepatol Commun 3,P.493-503 / 2019
Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization Proc Natl Acad Sci U S A 116,P.8487-8492 / 2019
Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K
Clinical evaluation of a newly developed chemiluminescent enzyme immunoassay in Japan for hepatitis C virus core antigen. Jpn J Infect Dis 72,P.285-291 / 2019
Inoue T, Ohike T, Ohne K, Sato S, Goto T, Tanaka Y.
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther 49,P.1230-1241 / 2019
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. A Ann Surg Oncol 26,P.1385-1393 / 2019
Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.
The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection. Aliment Pharmacol Ther 49,P.1060-1070 / 2019
Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, Ochiya T, Tanaka Y
CMCDG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus Antimicrob Agents Chemother 63,P.e02143 / 2019
Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori S-I, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, Mitsuya H
Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection Hepatol Res 49,P.512-520 / 2019
Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T
Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma J Gastroenterol 54,P.427-436 / 2019
Raksayot M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Treeprasertsuk S, Poovorawan Y, Tanaka Y, Tangkijvanich P
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk Aliment Pharmacol Ther 49,P.107-115 / 2019
Hsu Y-C, Nguyen MH, Mo L-R, Wu M-S, Yang T-H, Chen C-C, Tseng C-H, Tai C-M, Wu C-Y, Lin J-T, Tanaka Y, Chang C-Y
TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy J Gastroenterol 54,P.339-346 / 2019
Iio E, Matsuura K, Shimada N, Atsukawa M, Itokawa N, Abe H, Kato K, Takaguchi K, Senoh T, Eguchi Y, Nomura H, Yoshizawa K, Kang J-H, Matsui T, Hirashima N, Kusakabe A, Miyaki T, Fujiwara K, Matsunami K, Tsutsumi S, Iwakiri K, Tanaka Y
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy Blood 133,P.137-146 / 2019
Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K
Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study Hepatol Res 49,P.125-135 / 2019
Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita A-N, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K
Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial J Gastroenterol 54,P.87-95 / 2019
Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study J Gastroenterol Hepatol 34,P.364-369 / 2019
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K
An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People Hepatology 69,P.19-33 / 2019
Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, Kawashima K, Murakami S, Takahashi S, Isogawa M, Ikeo K, Mizokami M, McMahon BJ, Tanaka Y
-
-
-
英語論文
-
